>
产品中心 >
Other_reagents >
Adipogen/Neutral-ODN (Control for iODNs) Endotoxin-free (sterile)/IAX-200-202-3001/3 x 1 mg
| ProductDetails | |
|---|---|
| Synonyms | NegativeControlforinhibitoryODNs(iODNs)andCpGODNs(TLR9agoNISTs) |
| ProductType | Chemical |
| Properties | |
| MW | 4,821g/mol |
| Sequence | 5’-tcctgcaggttaagt-3’(lowercaseletters:phosphorothioatelinkage:nucleaseresistant) |
| Reconstitution | Fora100μMstocksolution,dissolvetotalvialcontentin2074μl(1mgsize)or207μl(100μgsize)sterileendotoxin-freewaterorPBS. |
| Formulation | Lyophilized.Sterile. |
| BIOLOGicalActivity | NegativecontrolODNwithoutagonisticnorantagonisticactivity(neutral)forinvivouseinrodents(50-150μgperinjection). |
| Crossreactivity | Human Mouse Rat |
| Specificity | Human,Mouse,Rat |
| EndotoxinContent | <0.002eu g=""> |
| Declaration | ManufacturedbyInnaxon. |
| OtherProductData | Contains:100μgsizeincludes1.5mlddWaterEndotoxin-free(sterile)(Cat.No.:IAX-900-002-LD15).1mgand3x1mgsizeseachinclude10mlddWaterEndotoxin-free(sterile)(Cat.No.:IAX-900-002-L010). |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | +4°C |
| HandlingAdvice | Avoidfreeze/thawcycles. Afterreconstitution,preparealiquotsandkeepaqueousstocksolutionsfor1dayat4°Corstoreat-20°C(shelf-life6months). |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat+4°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
Inrecentyearsseveralgroupshavestudiedthesequencerequirements,specificity,signallingpathwaysandkineticsoftheTLR(Toll-likereceptor)9suppressionbyinhibitoryoligonucleotidemotifs,whichledtoaclassofnovelinhibitoryoligonucleotide(iODNs),thatisindependentofthepreviouslythoughtspeciespreference.SubsequentlyithasbeendiscoveredthattelomericDNArepeats(TTAGGG)ncanblockimmuneactivationbyCpG-ODNs.Short,11-15baselongoligonucleotidesweresynthesizedthatwerecapableofpotentlyinhibitingCpG-stimulation.TheoptimalinhibitoryDNAmotifconsistsofapyrimidine-richtriplet,preferablyCCT,whichispositioned5-totheGGGsequenceinasinglestrandedDNAmolecule.Additionally,boththeoptimalspacingbetweentheCCTandGGGmotifs,aswellastheirrelativeordertoeachother,isofcrucialimportancefortheinhibitoryDNAaction.Interestingly,althoughbothTLR7/TLR8ligandsandbacterialDNAsharetheendosomalcompartmentforreceptorbindingandsignaltransduction,certainiODNs(G-type)suppressonlyTLR9-mediatedactivation,whereasprototypeclassIiODNmayalsointerferewiththeactivationviatheTLR7/TLR8pathway.Recently,intriguingevidencehasbeenpresentedthatforsomeiODNclassestheimmuno-modulatorybiologicalactivityshowsonlylimitedsequencedependencyormaynoteveninvolveTLR-mediateduptakeandsignalingpathways.ForexampleiODNsoftheclassIIarethoughttoactonimmuneactivationthroughinhibitionofSTATsignalingandindependentofTLRsignalingviabindingtoayettobeidentified"ODN-receptor".SlightlymodifiedphosphodiesterversionsofthemostpotentinhibitoryODNswerealsoabletoprofoundlyblocktheimmuneactivationofmacrophagesandjustrecentlyprovetobevaluabletoolsforinvivouseinexperimentalanimalmodelsofinflammatoryandauto-immunediseases.BasedupontheserecentinsightsthefollowingclassificationforiODNshasbeensuggested:
ClassI:G-stretchODNs:TLR9-specificcompetitors,someiODNsmayalsoaffectTLR7andTLR8signaling
ClassII:ODNswithtelomericrepeats:TLR-independentinhibitorsofSTATsignalling(cellularuptakeviaan"ODNreceptor"?)
ClassIII:InhibitorsofDNAuptakeinasequenceindependentmanner
ClassIV:LongphosphorothioateODNsasdirectcompetitorsofTLR9signalinginasequenceindependentmanner
- DNAMotifssuppressingTLR9responses:A.Trieu,etal.;Crit.Rev.Immunol.26,527(2006)
- Inhibitoryoligodeoxynucleotides-therapeuticpromiseforsystemicautoimmunediseases?P.Lenert;Clin.Exp.Immunol.140,1(2005)
- Immunotherapeuticutilityofstimulatoryandsuppressiveoligodeoxynucleotides:K.J.Ishii,etal.;Curr.Opin.Mol.Ther.6,166(2004)
- Suppressiveoligodeoxynucleotidesprotectmicefromlethalendotoxicshock:H.Shirota,etal.;J.Immunol.174,4579(2005)
- Toll-likereceptor9inhibitionreducesmortalityinpolymicrobialsepsis:G.Plitas,etal.;J.Exp.Med.205,1277(2008)
